There is no FDA-approved MOTS-c dosage protocol, and there is no established medical dosing standard 8, 9. Online MOTS-c protocols describe investigational or practice-based use, not labeled treatment guidance. Because MOTS-c is an emerging mitochondrial peptide, any use should be discussed with a licensed clinician who can review risks, goals, medications, and lab monitoring 1.
Wondering if NAD+ is right for you? Take the 3-min clinical quiz.
See if you qualify →What should patients know before looking at a MOTS-c dosage protocol?
MOTS-c is best viewed as an investigational peptide, not a medication with a standard protocol. The most important fact is no FDA-approved dosing exists, so a chart online cannot tell you what is safe or right for you.
MOTS-c is also called mitochondrial open reading frame of the 12S rRNA type-c. It is a mitochondria-derived peptide, sometimes called a mitokine, because it appears to help mitochondria communicate with the rest of the cell and body 1.
Quick facts about MOTS-c
FDA status
MOTS-c has no FDA-approved brand name, no labeled indication, and no established international nonproprietary name listed for prescribing use. On July 23, 2026, the FDA Pharmacy Compounding Advisory Committee recommended MOTS-c for inclusion on the 503A Bulks List by advisory vote, but the FDA’s final determination is still pending 8, 9.
Established dosage status
There is no official MOTS-c dosage chart for patients. Published research has focused on biology and early translation, not a labeled dose schedule for clinical care 1, 2.
Common route discussed online
Public online protocols often discuss subcutaneous injection, meaning an injection under the skin. That route is a common peptide-clinic format, but it is not the same as an FDA-labeled route for MOTS-c.
Main research interest
The main research interest is cellular energy metabolism, including AMPK signaling, glucose handling, insulin sensitivity, exercise response, and aging-related mitochondrial signaling 1, 3.
Key safety takeaway
The key safety issue is uncertainty. MOTS-c has plausible metabolic effects, so people with diabetes, prediabetes, kidney disease, liver disease, cancer history, pregnancy, or complex medication lists should not treat an online schedule as a substitute for clinician review.
What is MOTS-c?
MOTS-c is a small peptide encoded by mitochondrial DNA, not the nuclear DNA that carries most human genes. It is 16 amino acids long and was first described as a signal involved in metabolic homeostasis 1.
What the name MOTS-c means
MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. In plain language, it is a short protein-like signal made from instructions inside the mitochondria, the parts of cells that help turn food into usable energy 1.
Why mitochondrial DNA makes MOTS-c unusual
Most peptides are encoded by nuclear DNA. MOTS-c is unusual because it comes from mitochondrial DNA, which is why researchers study it as a possible link between mitochondrial health, metabolism, and aging biology 1, 3.
Natural MOTS-c versus manufactured or compounded MOTS-c
Your body naturally produces MOTS-c. Manufactured or compounded MOTS-c refers to a peptide made outside the body for possible use when prescribed by other licensed providers; Chia does not currently offer MOTS-c. Any compounded medication should come from an appropriate licensed pharmacy after a clinician determines it is appropriate.
Is there an official MOTS-c dosage chart?
No. MOTS-c does not have an FDA-approved label, so there is no official dosage chart that tells patients how much to use, how often to inject, or how long a cycle should last.
Why no FDA-approved dosing exists
FDA-approved dosing is usually based on controlled trials that evaluate dose, safety, benefit, side effects, and special populations. MOTS-c has not gone through that process for a labeled indication, so online charts should not be read like prescription instructions.
Why online protocols may differ
Online protocols may differ because they are often based on clinic practice, seller guidance, extrapolation from preclinical research, or unpublished experience. Those inputs can generate a schedule, but they do not establish a medical standard.
What a responsible dosage chart can and cannot show
| What a chart may show | What it cannot prove |
|---|---|
| Reported dose ranges used by some clinics or peptide sellers | That the range is safe or effective for you |
| Commonly discussed injection frequency or cycle length | That the schedule was validated in controlled human trials |
| Suggested lab markers to discuss with a clinician | That lab changes equal longer life or disease prevention |
| Questions to ask about pharmacy quality and sterility | That a research-chemical product is safe for personal use |
What do online MOTS-c protocols usually include?
Online MOTS-c protocols usually include a dose amount, subcutaneous injection frequency, and a cycle length. These are reported protocols, not FDA-approved dosing instructions.
Examples of public online guides describe practice-based ranges such as 2.5 to 10 mg per injection or 5 to 10 mg per week, with injections split across several days 10, 11. These numbers are included here only to explain what patients may see online, not to recommend a dose.
| Protocol element | What patients may see online | Responsible interpretation |
|---|---|---|
| Dose amount | Milligram-based ranges, often framed as low, moderate, or higher | Investigational or practice-based; not a personal dosing plan |
| Route | Subcutaneous injection | Commonly discussed, but not an FDA-labeled route for MOTS-c |
| Frequency | Several times weekly or cycle-based schedules | Not proven as a clinical standard |
| Cycle length | Weeks on therapy followed by a break | Varies widely and should not be copied without clinician review |
| Monitoring | Glucose, fasting insulin, HbA1c, body composition, symptoms | Reasonable discussion points, but monitoring should be individualized |
Why these are not the same as proven clinical standards
A proven clinical standard comes from trials that define who was studied, what dose was used, what outcomes changed, and what side effects occurred. For MOTS-c, that patient-level evidence is still limited, so individual results and risks are uncertain.
What evidence exists for MOTS-c in humans?
Human MOTS-c evidence is early. The strongest human work so far looks at physiology, circulating levels, genetics, and metabolic biomarkers, not a proven treatment protocol.
Human physiology and biomarker studies
Researchers have measured MOTS-c in human blood and studied how levels relate to age, exercise, obesity, insulin resistance, and metabolic disease markers. These studies can show associations, but they cannot prove that taking MOTS-c improves health outcomes 2, 4.
Early clinical research questions
A key question is whether MOTS-c can influence insulin sensitivity or metabolic health in humans in a way that is safe, durable, and clinically meaningful. That requires controlled human trials with clear endpoints, adverse-event tracking, and enough follow-up time.
What has not been proven in humans
- MOTS-c has not been proven to cause long-term weight loss in humans.
- MOTS-c has not been proven to prevent diabetes, heart disease, or aging-related disease.
- MOTS-c has not been proven to extend human lifespan.
- MOTS-c has not been proven to replace GLP-1 medications, nutrition care, exercise, or diabetes treatment.
What have animal and cell studies suggested about MOTS-c?
Animal and cell studies suggest MOTS-c may affect metabolic signaling, but those findings are not the same as patient benefits. In the first major MOTS-c paper, researchers reported effects on metabolic homeostasis in mice and cell systems 1.
Metabolism and insulin-signaling pathways
Preclinical work has linked MOTS-c to AMPK, a cellular energy sensor involved in glucose use and fatty-acid metabolism 1. This is why MOTS-c is often discussed in relation to insulin resistance and metabolic health, but pathway effects do not prove a treatment benefit.
Exercise-response mechanisms
Some research suggests MOTS-c may be involved in exercise-related metabolic adaptation and stress-response signaling 3. That does not mean an injection can replace exercise or reproduce all exercise benefits.
Aging-related hypotheses
Mitochondrial function changes with age, and MOTS-c is studied as part of that biology. Some human genetics and observational work links mitochondrial peptides with healthy aging traits, but this does not prove that using MOTS-c extends life 5.
Why animal and cell findings cannot be treated as patient benefits
Cells and mice are useful for learning mechanisms. Patients are more complex. Dose, route, metabolism, side effects, medication interactions, and long-term risks can all differ in humans.
What safety questions should be asked before using MOTS-c?
Before considering MOTS-c, the safety conversation should focus on medical history, medications, metabolic risk, labs, and product quality. A licensed clinician is the right person to decide whether any peptide is appropriate.
Medical history and medication review
A clinician should review diabetes medicines, blood-pressure drugs, cancer history, autoimmune disease, kidney or liver disease, pregnancy status, and prior reactions to injections. This matters because MOTS-c is studied for metabolic signaling, and metabolic signals can overlap with real medical conditions.
Metabolic conditions such as diabetes or prediabetes
People with diabetes or prediabetes need extra caution because changes in appetite, glucose patterns, insulin sensitivity, or exercise habits can affect medication needs. Standard diabetes care uses validated tests such as fasting glucose, HbA1c, and sometimes fasting insulin or other markers under clinician guidance 6.
Lab monitoring questions to discuss with a clinician
- Which baseline labs are appropriate for my goals and medical history?
- Should glucose, HbA1c, fasting insulin, lipids, kidney function, or liver enzymes be checked?
- How would we define benefit, side effects, or a reason to stop?
- What symptoms should prompt urgent medical care?
- How will this interact with my current medications or supplements?
Product quality, sterility, and compounding concerns
The main safety divide is licensed versus unlicensed access. A prescription product from an appropriate state-licensed 503A compounding pharmacy is different from a no-prescription vial sold online as a research chemical. Sterility, potency, storage, and chain of custody matter for any injectable product 7.
How does MOTS-c compare with longevity peptides Chia does offer?
Chia does not currently offer MOTS-c. When patients are interested in longevity peptides, we focus on clinician-reviewed options in our live catalog, including sermorelin, NAD+, glutathione, and GHK-Cu cream.
At Chia, treatment starts with a short online health questionnaire. A licensed US provider reviews it and prescribes only when clinically appropriate; a prescription is never guaranteed. Medications are compounded in the US by state-licensed 503A pharmacies and shipped to the patient’s door.
| Option | Chia forms | Current starting price | How to think about it |
|---|---|---|---|
| MOTS-c | Not offered by Chia | Not applicable | Education-only; no FDA-approved dosage protocol |
| Sermorelin | Injection, nasal spray, tablets | From $179/mo | A GH-axis peptide option to discuss with a licensed provider |
| NAD+ | Injection, nasal spray | From $179/mo injection; from $119/mo nasal spray | A cellular metabolism and wellness option in Chia’s catalog |
| Glutathione | Injection, nasal spray | From $179/mo | An antioxidant-support option in Chia’s catalog |
| GHK-Cu Cream | Cream | From $159/mo | A topical skin-focused peptide option |
| Foundation Longevity | Sermorelin Injection + NAD+ Injection + Glutathione Injection | From $399/mo | A multi-treatment protocol for patients who want one clinician-reviewed longevity plan |
For patients who want a structured longevity discussion, our Foundation Longevity protocol combines Sermorelin Injection, NAD+ Injection, and Glutathione Injection. You can also start with the online eligibility quiz to see whether a Chia provider review may fit your goals. Compounded medications are not FDA-approved.
How can patients evaluate a MOTS-c source or peptide clinic?
If you are researching MOTS-c, evaluate the care model before you evaluate the vial. The core question is whether a licensed clinician and a licensed pharmacy are involved from the start.
Confirm whether a licensed clinician evaluates eligibility
A real evaluation should include medical history, medications, allergies, goals, contraindications, and follow-up. A website that sells peptides without a prescription is not a substitute for medical care.
Ask whether prescriptions are filled by a state-licensed pharmacy
For compounded prescriptions, ask whether a state-licensed 503A pharmacy is used and whether sterility and potency testing processes are documented. This does not make a compounded drug FDA-approved, but it is a key quality difference versus unlicensed sellers.
Avoid products sold as research chemicals for personal use
Products labeled “for research use only” are not intended for personal treatment. They may lack the quality controls, clinician oversight, and pharmacy standards expected for a prescription product.
Keep expectations tied to evidence, not marketing claims
MOTS-c is interesting science. It is not an established treatment for weight loss, diabetes, aging, or performance. If a clinic promises outcomes, ask what human trial supports that exact claim and what risks were tracked.
There is no official or FDA-approved MOTS-c dose. Online protocols often list milligram ranges, but those are investigational or practice-based and should not be used as personal dosing instructions.
There is no established MOTS-c schedule. Some online protocols describe cycles or several injections per week, but these are not proven clinical standards.
No. MOTS-c has no FDA-approved brand name, labeled indication, or dosage protocol. PCAC recommended MOTS-c for the 503A Bulks List in July 2026, but FDA’s final determination is pending.
MOTS-c is studied for metabolic signaling, insulin sensitivity, and mitochondrial biology, but it is not proven as a weight-loss treatment in humans.
No. MOTS-c is a mitochondria-derived peptide studied for cellular energy signaling. GLP-1 medicines act on incretin pathways that affect appetite, insulin, and glucose regulation.
No. Chia does not currently offer MOTS-c. Chia’s longevity catalog includes options such as sermorelin, NAD+, glutathione, and GHK-Cu cream, when prescribed after clinician review.
Ask about your medical history, medication interactions, pregnancy status, lab monitoring, expected benefits, side effects, when to stop, and whether the prescription is filled by a state-licensed pharmacy.
References
- 1.Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015.
- 2.Du C, Zhang C, Wu W, et al. Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance. Pediatric Diabetes. 2018.
- 3.Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021.
- 4.Cataldo LR, Fernández-Verdejo R, Santos JL, Galgani JE. Plasma MOTS-c levels are associated with insulin sensitivity in lean but not obese individuals. Journal of Investigative Medicine. 2018.
- 5.Fuku N, Pareja-Galeano H, Zempo H, et al. The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity? Aging Cell. 2015.
- 6.American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2026. Diabetes Care. 2026.
- 7.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA. 2024. Retrieved August 18, 2026.
- 8.U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting Materials, July 23-24, 2026. FDA. 2026. Retrieved August 18, 2026.
- 9.Drug Topics. PCAC recommends six peptides for 503A Bulks List inclusion, including MOTS-c, while FDA final action remains pending. Drug Topics. 2026.
- 10.Healthspan. MOTS-C Dosage Chart: Protocol Guide for Metabolic Health and Performance. Healthspan. 2026.
- 11.Perfect B. MOTS-c Dosage: Per Day, Per Week and Cycle Guide. Perfect B. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if NAD+ is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
